Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anebulo PharmaceuticalsFRA:214 35 Market Cap is €20.29 Mil as of Aug. 01, 2026. GuruFocus rates FRA:214 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,422 Biotechnology companies, Anebulo Pharmaceuticals ranks worse than 80.8% on this metric.
Anebulo Pharmaceuticals's quarterly market cap
increased
from Jun. 2025 (€49.30 Mil) to Sep. 2025 (€81.76 Mil) but then
declined
from Sep. 2025 (€81.76 Mil) to Dec. 2025 (€55.46 Mil).
Anebulo Pharmaceuticals's annual market cap
increased
from Jun. 2023 (€53.32 Mil) to Jun. 2024 (€62.76 Mil) but then
declined
from Jun. 2024 (€62.76 Mil) to Jun. 2025 (€49.30 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anebulo Pharmaceuticals's Enterprise Value for Today is €12.54 Mil.
Anebulo Pharmaceuticals (FRA:214) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Anebulo Pharmaceuticals Market Cap Related Terms
Anebulo Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:214 vs PHIO, COCP, CALC: Market Cap Comparison
For the Biotechnology subindustry, Anebulo Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anebulo Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Anebulo Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Anebulo Pharmaceuticals's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anebulo Pharmaceuticals (FRA:214) has a Market Cap of €20.29 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anebulo Pharmaceuticals and its competitors. According to the industry distribution chart, Anebulo Pharmaceuticals ranks #1149 out of 1422 companies in the Biotechnology industry, placing it in the top 80.8%.
Is Anebulo Pharmaceuticals' Market Cap too high?
Anebulo Pharmaceuticals' current Market Cap is €20.29 Mil. Based on the distribution chart, Anebulo Pharmaceuticals ranks #1149 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anebulo Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Anebulo Pharmaceuticals' Market Cap compare to PHIO and COCP?
According to the Biotechnology industry distribution chart, Anebulo Pharmaceuticals ranks #1149 out of 1422 companies for Market Cap. This places Anebulo Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 109.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 109.62, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anebulo Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 109.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anebulo Pharmaceuticals's current Market Cap is €20.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anebulo Pharmaceuticals stock overvalued right now?
Anebulo Pharmaceuticals (FRA:214) has a current Market Cap of €20.29 Mil. The current Market Cap is €20.29 Mil. Anebulo Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Anebulo Pharmaceuticals (FRA:214), the current Market Cap is €20.29 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score
Get the complete analysis for FRA:214
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:214 has been successfully added to your 
